利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.017 秒)

    Reagents and methods for sirtuin capture
    1.
    发明授权
    Reagents and methods for sirtuin capture 有权
    sirtuin捕获的试剂和方法

    公开(公告)号：US09290791B2

    公开(公告)日：2016-03-22

    申请号：US13698561

    申请日：2011-05-18

    申请人： Anthony A. Sauve ,  Yana Cen

    发明人： Anthony A. Sauve ,  Yana Cen

    IPC分类号： G01N33/573 ,  C12N9/98 ,  A61K38/06 ,  C07K5/00 ,  C07K7/00 ,  C07K16/00 ,  C07K17/00 ,  C07H19/00 ,  C12Q1/34

    CPC分类号： C12Q1/34 ,  C12Q2334/00 ,  G01N2333/918 ,  G01N2500/00

    摘要： The invention provides a method of preparing a sirtuin complex, a method for detecting a sirtuin in a sample, and a method of screening for compounds which inhibit the deacetylase activity of a sirtuin. The method includes (a) providing a sirtuin substrate having the formula: (b) providing NAD+ or an NAD+ analog having the formula: and (c) providing a sirtuin, wherein R1-R4, A1, A2, and n are as defined herein.

    摘要翻译： 本发明提供了一种制备沉默调节蛋白复合物的方法，用于检测样品中沉默调节蛋白的方法，以及筛选抑制沉默调节蛋白的脱乙酰酶活性的化合物的方法。 该方法包括（a）提供具有下式的沉默调节蛋白的底物：（b）提供具有下式的NAD +或NAD +类似物：（c）提供沉默调节蛋白，其中R1-R4，A1，A2和n如本文所定义 。

    2-FLUORINATED RIBOSES AND ARABINOSES AND METHODS OF USE AND SYNTHESIS
    3.
    发明申请
    2-FLUORINATED RIBOSES AND ARABINOSES AND METHODS OF USE AND SYNTHESIS 有权
    2-氟化R ES ES AND。。。。。。。。。。。。。。。。。。。。。

    公开(公告)号：US20120108535A1

    公开(公告)日：2012-05-03

    申请号：US13381587

    申请日：2010-07-01

    申请人： Anthony A. Sauve ,  Yana Cen

    发明人： Anthony A. Sauve ,  Yana Cen

    IPC分类号： A61K31/7028 ,  C07H19/048 ,  C07H23/00

    CPC分类号： C07H23/00 ,  C07H19/048 ,  C07H19/056 ,  C07H19/06 ,  C07H19/073 ,  C07H19/12 ,  C07H19/16 ,  C07H19/173 ,  C07H19/19

    摘要： Disclosed are halogenated 2-deoxy-lactone, 2′-deoxy-nucleosides, and derivatives thereof, for example, a compound of formula (I). Also disclosed are a composition comprising a pharmaceutically acceptable carrier and at least one compound or salt of the invention, and a method of treating a disorder is selected from the group consisting of an abnormal cellular proliferation, a viral infection, and an autoimmune disorder.

    摘要翻译： 公开了卤化的2-脱氧内酯，2'-脱氧核苷及其衍生物，例如式（I）的化合物。 还公开了包含药学上可接受的载体和本发明的至少一种化合物或盐的组合物，治疗病症的方法选自异常细胞增殖，病毒感染和自身免疫性疾病。

    SIR2 regulation
    5.
    发明授权
    SIR2 regulation 有权
    SIR2调节

    公开(公告)号：US08383653B2

    公开(公告)日：2013-02-26

    申请号：US10560676

    申请日：2004-06-30

    申请人： Vern L. Schramm ,  Anthony A. Sauve

    发明人： Vern L. Schramm ,  Anthony A. Sauve

    IPC分类号： A61K31/445

    CPC分类号： A61K31/4965 ,  A61K31/166 ,  A61K31/455 ,  A61K38/005 ,  C07D213/81 ,  C07D213/83 ,  C07D241/24 ,  C12Q1/34 ,  G01N2500/02

    摘要： Compounds are disclosed which inhibit SIR2 base exchange more than deacetylation, thus enhancing SIR2 deacetylation activity. Methods of using the compounds for enhancing SIR2 deacetylation activity and increasing longevity of an organism are also disclosed. Methods for screening for compounds that enhance SIR2 deacetylation activity and increase longevity of an organism are additionally disclosed.

    摘要翻译： 公开了抑制SIR2碱基交换比脱乙酰化的化合物，从而增强SIR2脱乙酰活性。 还公开了使用该化合物来提高SIR2脱乙酰活性和增加生物体寿命的方法。 还公开了用于筛选增强SIR2脱乙酰活性并增加生物体寿命的化合物的方法。

    Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases, and uses thereof
    6.
    发明授权
    Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases, and uses thereof 失效

    公开(公告)号：US07504489B2

    公开(公告)日：2009-03-17

    申请号：US11294932

    申请日：2005-12-05

    申请人： Anthony A. Sauve ,  Vern L. Schramm

    发明人： Anthony A. Sauve ,  Vern L. Schramm

    IPC分类号： C07H15/00 ,  C07H17/00 ,  C07H17/02 ,  C07G3/00 ,  C07G11/00

    CPC分类号： C07D405/04 ,  C07D307/20 ,  C07H19/04 ,  C07H19/10 ,  C07H19/20

    摘要： The present invention provides compounds having the formula: wherein A is chosen from a nitrogen-, oxygen-, or sulfur-linked aryl, alkyl, cyclic, or heterocyclic group; both B and C are hydrogen, or either B or C is a halogen, amino, or thiol group and the other of B or C is hydrogen; and D is a primary alcohol, a hydrogen, or an oxygen, nitrogen, carbon, or sulfur linked to phosphate, a phosphoryl group, a pyrophosphoryl group, or adenosine monophosphate through a phosphodiester or carbon-, nitrogen-, or sulfur-substituted phosphodiester bridge, or to adenosine diphosphate through a phosphodiester or carbon-, nitrogen-, or sulfur-substituted pyrophosphodiester bridge. The present invention also provides pharmaceutical compositions containing the above compounds, methods of using the above compounds as pharmaceuticals, and processes for preparing the above compounds.Also provided are methods for inhibiting an ADP-ribosyl transferase, ADP-ribosyl cyclase, or ADP-ribosyl hydrolase enzyme, and methods for treating a disease or condition associated with an ADP-ribosyl transferase, ADP-ribosyl cyclase, or ADP-ribosyl hydrolase enzyme in a subject in need of treatment thereof.

    Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases, and uses thereof
    7.
    发明授权
    Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases, and uses thereof 失效

    公开(公告)号：US07056894B2

    公开(公告)日：2006-06-06

    申请号：US10038760

    申请日：2002-01-04

    申请人： Anthony A. Sauve ,  Vern L. Schramm

    发明人： Anthony A. Sauve ,  Vern L. Schramm

    IPC分类号： A11N43/04 ,  A61K31/70 ,  C07H19/00 ,  C07H21/00

    CPC分类号： C07D405/04 ,  C07D307/20 ,  C07H19/04 ,  C07H19/10 ,  C07H19/20

    摘要： The present invention provides compounds having the formula: wherein A is chosen from a nitrogen-, oxygen-, or sulfur-linked aryl, alkyl, cyclic, or heterocyclic group; both B and C are hydrogen, or either B or C is a halogen, amino, or thiol group and the other of B or C is hydrogen; and D is a primary alcohol, a hydrogen, or an oxygen, nitrogen, carbon, or sulfur linked to phosphate, a phosphoryl group, a pyrophosphoryl group, or adenosine monophosphate through a phosphodiester or carbon-, nitrogen-, or sulfur-substituted phosphodiester bridge, or to adenosine diphosphate through a phosphodiester or carbon-, nitrogen-, or sulfur-substituted pyrophosphodiester bridge. The present invention also provides pharmaceutical compositions containing the above compounds, methods of using the above compounds as pharmaceuticals, and processes for preparing the above compounds.Also provided are methods for inhibiting an ADP-ribosyl transferase, ADP-ribosyl cyclase, or ADP-ribosyl hydrolase enzyme, and methods for treating a disease or condition associated with an ADP-ribosyl transferase, ADP-ribosyl cyclase, or ADP-ribosyl hydrolase enzyme in a subject in need of treatment thereof.

    Nicotyl riboside compositions and methods of use
    8.
    发明授权
    Nicotyl riboside compositions and methods of use 有权
    烟酰核糖苷组合物及其使用方法

    公开(公告)号：US09000147B2

    公开(公告)日：2015-04-07

    申请号：US13351411

    申请日：2012-01-17

    申请人： Anthony A. Sauve ,  Tianle Yang Redanz

    发明人： Anthony A. Sauve ,  Tianle Yang Redanz

    IPC分类号： C07H19/04 ,  C07H19/048

    CPC分类号： A61K31/706 ,  A61K31/351 ,  A61K45/06 ,  C07H1/00 ,  C07H19/048

    摘要： The invention relates to compositions of nicotinoyl ribosides and nicotinamide riboside derivatives and their methods of use. In some embodiments, the invention relates to methods of making nicotinoyl ribosides. In some embodiments, the invention relates to pharmaceutical compositions and nutritional supplements containing a nicotinoyl riboside. In further embodiments, the invention relates to methods of using nicotinoyl ribosides and nicotinamide riboside derivatives that promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for improving cell and tissue survival.

    摘要翻译： 本发明涉及烟酰基核糖苷和烟酰胺核苷衍生物的组合物及其使用方法。 在一些实施方案中，本发明涉及制备烟酰基核糖苷的方法。 在一些实施方案中，本发明涉及含有烟酰基核苷的药物组合物和营养补充剂。 在进一步的实施方案中，本发明涉及使用促进细胞和组织中细胞内水平的烟酰胺腺嘌呤二核苷酸（NAD +）增加细胞和组织存活的烟酰胺核糖苷和烟酰胺核苷衍生物的方法。